333 related articles for article (PubMed ID: 34290984)
1. Therapeutic Potential of Targeting Stromal Crosstalk-Mediated Immune Suppression in Pancreatic Cancer.
Du W; Pasca di Magliano M; Zhang Y
Front Oncol; 2021; 11():682217. PubMed ID: 34290984
[TBL] [Abstract][Full Text] [Related]
2. T-cell programming in pancreatic adenocarcinoma: a review.
Seo YD; Pillarisetty VG
Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
[TBL] [Abstract][Full Text] [Related]
3. Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy.
Martinez-Bosch N; Vinaixa J; Navarro P
Cancers (Basel); 2018 Jan; 10(1):. PubMed ID: 29301364
[TBL] [Abstract][Full Text] [Related]
4. Tumor Cell-Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer.
Das S; Shapiro B; Vucic EA; Vogt S; Bar-Sagi D
Cancer Res; 2020 Mar; 80(5):1088-1101. PubMed ID: 31915130
[TBL] [Abstract][Full Text] [Related]
5. Combination immunotherapy for pancreatic cancer: challenges and future considerations.
Gössling GCL; Zhen DB; Pillarisetty VG; Chiorean EG
Expert Rev Clin Immunol; 2022 Nov; 18(11):1173-1186. PubMed ID: 36045547
[TBL] [Abstract][Full Text] [Related]
6. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
[TBL] [Abstract][Full Text] [Related]
7. Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment.
Garcia Garcia CJ; Huang Y; Fuentes NR; Turner MC; Monberg ME; Lin D; Nguyen ND; Fujimoto TN; Zhao J; Lee JJ; Bernard V; Yu M; Delahoussaye AM; Jimenez Sacarello I; Caggiano EG; Phan JL; Deorukhkar A; Molkentine JM; Saur D; Maitra A; Taniguchi CM
Gastroenterology; 2022 Jun; 162(7):2018-2031. PubMed ID: 35216965
[TBL] [Abstract][Full Text] [Related]
8. Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma.
Skorupan N; Palestino Dominguez M; Ricci SL; Alewine C
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077755
[TBL] [Abstract][Full Text] [Related]
9. Myeloid Cell Mediated Immune Suppression in Pancreatic Cancer.
Kemp SB; Pasca di Magliano M; Crawford HC
Cell Mol Gastroenterol Hepatol; 2021; 12(5):1531-1542. PubMed ID: 34303882
[TBL] [Abstract][Full Text] [Related]
10. Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness.
Leca J; Martinez S; Lac S; Nigri J; Secq V; Rubis M; Bressy C; Sergé A; Lavaut MN; Dusetti N; Loncle C; Roques J; Pietrasz D; Bousquet C; Garcia S; Granjeaud S; Ouaissi M; Bachet JB; Brun C; Iovanna JL; Zimmermann P; Vasseur S; Tomasini R
J Clin Invest; 2016 Nov; 126(11):4140-4156. PubMed ID: 27701147
[TBL] [Abstract][Full Text] [Related]
11. Stroma and pancreatic ductal adenocarcinoma: an interaction loop.
Luo G; Long J; Zhang B; Liu C; Xu J; Ni Q; Yu X
Biochim Biophys Acta; 2012 Aug; 1826(1):170-8. PubMed ID: 22521638
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma.
Schmiechen ZC; Stromnes IM
Front Immunol; 2020; 11():613815. PubMed ID: 33584701
[TBL] [Abstract][Full Text] [Related]
13. Adding combination immunotherapy consisting of cancer vaccine, anti-PD-1 and anti-CSF1R antibodies to gemcitabine improves anti-tumor efficacy in murine model of pancreatic ductal adenocarcinoma.
Saung MT; Zheng L
Ann Pancreat Cancer; 2019 Dec; 2():. PubMed ID: 32405624
[TBL] [Abstract][Full Text] [Related]
14. The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions.
Herting CJ; Karpovsky I; Lesinski GB
Cancer Metastasis Rev; 2021 Sep; 40(3):675-689. PubMed ID: 34591240
[TBL] [Abstract][Full Text] [Related]
15. Role of the tumor microenvironment in pancreatic adenocarcinoma.
Sun XJ; Jiang TH; Zhang XP; Mao AW
Front Biosci (Landmark Ed); 2016 Jun; 21(1):31-41. PubMed ID: 26709759
[TBL] [Abstract][Full Text] [Related]
16. Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease.
Hutcheson J; Balaji U; Porembka MR; Wachsmann MB; McCue PA; Knudsen ES; Witkiewicz AK
Clin Cancer Res; 2016 Jul; 22(14):3606-17. PubMed ID: 26858311
[TBL] [Abstract][Full Text] [Related]
17. Tissue Transglutaminase Activates Cancer-Associated Fibroblasts and Contributes to Gemcitabine Resistance in Pancreatic Cancer.
Lee J; Yakubov B; Ivan C; Jones DR; Caperell-Grant A; Fishel M; Cardenas H; Matei D
Neoplasia; 2016 Nov; 18(11):689-698. PubMed ID: 27792935
[TBL] [Abstract][Full Text] [Related]
18. Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk.
Orozco CA; Martinez-Bosch N; Guerrero PE; Vinaixa J; Dalotto-Moreno T; Iglesias M; Moreno M; Djurec M; Poirier F; Gabius HJ; Fernandez-Zapico ME; Hwang RF; Guerra C; Rabinovich GA; Navarro P
Proc Natl Acad Sci U S A; 2018 Apr; 115(16):E3769-E3778. PubMed ID: 29615514
[TBL] [Abstract][Full Text] [Related]
19. Activating Immune Recognition in Pancreatic Ductal Adenocarcinoma via Autophagy Inhibition, MEK Blockade, and CD40 Agonism.
Jiang H; Courau T; Borison J; Ritchie AJ; Mayer AT; Krummel MF; Collisson EA
Gastroenterology; 2022 Feb; 162(2):590-603.e14. PubMed ID: 34627860
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1.
Wang K; Zhan Y; Huynh N; Dumesny C; Wang X; Asadi K; Herrmann D; Timpson P; Yang Y; Walsh K; Baldwin GS; Nikfarjam M; He H
Cancer Lett; 2020 Mar; 472():8-18. PubMed ID: 31857154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
